Sarepta’s news came as several companies—including Dyne Therapeutics, REGENXBIO and Genethon—presented new data on their next-generation exon-skipping therapies and gene therapies for Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback